Literature DB >> 15542562

Insights into saquinavir resistance in the G48V HIV-1 protease: quantum calculations and molecular dynamic simulations.

Kitiyaporn Wittayanarakul1, Ornjira Aruksakunwong, Suwipa Saen-oon, Wasun Chantratita, Vudhichai Parasuk, Pornthep Sompornpisut, Supot Hannongbua.   

Abstract

The spread of acquired immune deficiency syndrome has increasingly become a great concern owing largely to the failure of chemotherapies. The G48V is considered the key signature residue mutation of HIV-1 protease developing with saquinavir therapy. Molecular dynamics simulations of the wild-type and the G48V HIV-1 protease complexed with saquinavir were carried out to explore structure and interactions of the drug resistance. The molecular dynamics results combined with the quantum-based and molecular mechanics Poisson-Boltzmann surface area calculations indicated a monoprotonation took place on D25, one of the triad active site residues. The inhibitor binding of the triad residues and its interaction energy in the mutant were similar to those in the wild-type. The overall structure of both complexes is almost identical. However, the steric conflict of the substituted valine results in the conformational change of the P2 subsite and the disruption of hydrogen bonding between the -NH of the P2 subsite and the backbone -CO of the mutated residue. The magnitude of interaction energy changes was comparable to the experimental K(i) data. The designing for a new drug should consider a reduction of steric repulsion on P2 to enhance the activity toward this mutant strain.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15542562      PMCID: PMC1305161          DOI: 10.1529/biophysj.104.046110

Source DB:  PubMed          Journal:  Biophys J        ISSN: 0006-3495            Impact factor:   4.033


  43 in total

Review 1.  New challenges in quantum chemistry: Quests for accurate calculations for large molecular systems.

Authors:  Keiji Morokuma
Journal:  Philos Trans A Math Phys Eng Sci       Date:  2002-06-15       Impact factor: 4.226

Review 2.  HIV protease inhibition: limited recent progress and advances in understanding current pitfalls.

Authors:  Fátima Rodríguez-Barrios; Federico Gago
Journal:  Curr Top Med Chem       Date:  2004       Impact factor: 3.295

Review 3.  Peptidomimetic inhibitors of HIV protease.

Authors:  John T Randolph; David A DeGoey
Journal:  Curr Top Med Chem       Date:  2004       Impact factor: 3.295

4.  X-ray crystallographic structure of a complex between a synthetic protease of human immunodeficiency virus 1 and a substrate-based hydroxyethylamine inhibitor.

Authors:  A L Swain; M M Miller; J Green; D H Rich; J Schneider; S B Kent; A Wlodawer
Journal:  Proc Natl Acad Sci U S A       Date:  1990-11       Impact factor: 11.205

5.  Human immunodeficiency virus protease expressed in Escherichia coli exhibits autoprocessing and specific maturation of the gag precursor.

Authors:  C Debouck; J G Gorniak; J E Strickler; T D Meek; B W Metcalf; M Rosenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1987-12       Impact factor: 11.205

6.  Rational design of peptide-based HIV proteinase inhibitors.

Authors:  N A Roberts; J A Martin; D Kinchington; A V Broadhurst; J C Craig; I B Duncan; S A Galpin; B K Handa; J Kay; A Kröhn
Journal:  Science       Date:  1990-04-20       Impact factor: 47.728

Review 7.  Treatment of antiretroviral-drug-resistant HIV-1 infection.

Authors:  Steven G Deeks
Journal:  Lancet       Date:  2003-12-13       Impact factor: 79.321

8.  Efficiency of a second-generation HIV-1 protease inhibitor studied by molecular dynamics and absolute binding free energy calculations.

Authors:  M Lepsík; Z Kríz; Z Havlas
Journal:  Proteins       Date:  2004-11-01

9.  Human immunodeficiency virus 1 protease expressed in Escherichia coli behaves as a dimeric aspartic protease.

Authors:  T D Meek; B D Dayton; B W Metcalf; G B Dreyer; J E Strickler; J G Gorniak; M Rosenberg; M L Moore; V W Magaard; C Debouck
Journal:  Proc Natl Acad Sci U S A       Date:  1989-03       Impact factor: 11.205

10.  Viability of a drug-resistant human immunodeficiency virus type 1 protease variant: structural insights for better antiviral therapy.

Authors:  Moses Prabu-Jeyabalan; Ellen A Nalivaika; Nancy M King; Celia A Schiffer
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

View more
  15 in total

1.  Spin labeling and Double Electron-Electron Resonance (DEER) to Deconstruct Conformational Ensembles of HIV Protease.

Authors:  Thomas M Casey; Gail E Fanucci
Journal:  Methods Enzymol       Date:  2015-09-01       Impact factor: 1.600

2.  Ligand configurational entropy and protein binding.

Authors:  Chia-en A Chang; Wei Chen; Michael K Gilson
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-22       Impact factor: 11.205

3.  Insights into the functional role of protonation states in the HIV-1 protease-BEA369 complex: molecular dynamics simulations and free energy calculations.

Authors:  Jianzhong Chen; Maoyou Yang; Guodong Hu; Shuhua Shi; Changhong Yi; Qinggang Zhang
Journal:  J Mol Model       Date:  2009-03-18       Impact factor: 1.810

4.  An insight to the molecular interactions of the FDA approved HIV PR drugs against L38L↑N↑L PR mutant.

Authors:  Zainab K Sanusi; Thavendran Govender; Glenn E M Maguire; Sibusiso B Maseko; Johnson Lin; Hendrik G Kruger; Bahareh Honarparvar
Journal:  J Comput Aided Mol Des       Date:  2018-02-03       Impact factor: 3.686

5.  Can cyclic HIV protease inhibitors bind in a non-preferred form? An ab initio, DFT and MM-PB(GB)SA study.

Authors:  Daniel P Oehme; Robert T C Brownlee; David J D Wilson
Journal:  J Mol Model       Date:  2012-11-13       Impact factor: 1.810

6.  Computational mutation scanning and drug resistance mechanisms of HIV-1 protease inhibitors.

Authors:  Ge-Fei Hao; Guang-Fu Yang; Chang-Guo Zhan
Journal:  J Phys Chem B       Date:  2010-07-29       Impact factor: 2.991

7.  Energetic basis for drug resistance of HIV-1 protease mutants against amprenavir.

Authors:  Parimal Kar; Volker Knecht
Journal:  J Comput Aided Mol Des       Date:  2012-02-14       Impact factor: 3.686

8.  Drug-resistant molecular mechanism of CRF01_AE HIV-1 protease due to V82F mutation.

Authors:  Xiaoqing Liu; Zhilong Xiu; Ce Hao
Journal:  J Comput Aided Mol Des       Date:  2009-02-15       Impact factor: 3.686

Review 9.  Therapeutic strategies underpinning the development of novel techniques for the treatment of HIV infection.

Authors:  Jian J Tan; Xiao J Cong; Li M Hu; Cun X Wang; Lee Jia; Xing-Jie Liang
Journal:  Drug Discov Today       Date:  2010-01-22       Impact factor: 7.851

10.  Evaluating the potency of HIV-1 protease drugs to combat resistance.

Authors:  Tingjun Hou; William A McLaughlin; Wei Wang
Journal:  Proteins       Date:  2008-05-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.